Welcome to our dedicated page for Shineco news (Ticker: SISI), a resource for investors and traders seeking the latest updates and insights on Shineco stock.
Shineco Inc. develops and commercializes induced pluripotent stem cell technology platforms and has also described its business as providing innovative diagnostic medical products and related medical devices. Company news commonly covers biological cell assets, iPSC and mesenchymal stem cell initiatives, molecular detection kits, health products, and subsidiary activity across InfiniClone, Dong'ao Health and Fuzhou Meidashan Biotechnology.
Recurring developments include technology service contracts, cell-storage and blockchain-based cell-asset programs, strategic distribution and cooperation agreements, phospholipid extraction technology, Southeast Asian market expansion, reverse stock split actions, insider stock-purchase plans, equity financing, acquisitions, and Nasdaq listing-compliance matters.
Shineco, Inc. announces the development of a revolutionary natural active water-soluble product extracted from soybean gum. This breakthrough technology aims to provide high-quality phospholipids essential for cell health and function. The product is set to address global nutritional deficiencies and offer diverse applications in medicine, functional foods, and beauty products.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Shineco, Inc. (NASDAQ: SISI) recently announced that its Cardiac 5-Minute Test has successfully passed quality inspection by China's NMPA, a significant milestone for its marketing in China. This test, developed by Shineco's subsidiary Biowin, is designed to quickly detect early-stage myocardial infarction, providing results in under 5 minutes, compared to over 20 minutes for existing tests. The NMPA's thorough evaluation focused on sensitivity, specificity, accuracy, and stability. Shineco aims to leverage this breakthrough in the Point-of-Care Testing market, which has a global potential of $3.5 billion.